To Evaluate the Efficacy and the Safety of Monthly Versus Weekly Oral Risedronate With Vitamin D in Compliance, Improvement of Vitamin D and BMD in Korean Postmenopausal Osteoporotic Women

Inclusion Criteria: 1. Female osteoporosis patients over 19years of age(with menopause). Definition of osteporosis * They had a BMD T-score -2.5 or less at mean Lumbar spine(L1\~L4), Femoral neck or total. Or evidence of at least one vertebral fracture. Definition of menopause(can be one of three condition) * For 12months spontaneous amenorrhea * For 6months spontaneous amenorrhea with serum FSH(Follicle stimulating hormone) is 40 mlIU/mL and over * 6weeks after bilateral ovariectomy whether hysterectomy of not 2. Patients who can be treated with oral bisphosphonate drugs 3. Patients who have adequate to be measured DXA(Dual energy x-ray absorptiometry) 4. Patients who made a voluntary agreement after explanation of this study 5. Patients who participated in clinical trial(HL\_RSNP\_401) must have taken the Risenexplus and finish the study for 12 months. Exclusion Criteria: 1. Patients with esophagus disorder. 2. Patients administered with osteoprosis therapy(except calcium,Vit.D medication) within previous 3 months 3. Patients with serum calcium concentrations 8.0mg/dL under. 4. Patients with severe nephropathy(serum creatinine\> doulble of normal level 5. Patients with unable to sit upright or stand 30minutes.